Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

businesswire

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial – NEWSnet – News… as it used to be

More Press Releases

April 30, 2026

Leading the AI Wave: E&R Brings Next-Gen Laser and Plasma Tech to SEMICON SEA 2026

April 30, 2026

Chinese Top 3 Roll Laminator Manufacturer in 2026: Leading the Industry with Innovative Laminating Technology

April 30, 2026

Dr. Mohana Rao Patibandla Highlights 3 Advanced Pediatric Neurosurgery Techniques Following INDSPNCON 2026 Presentations

April 30, 2026

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Leading the AI Wave: E&R Brings Next-Gen Laser and Plasma Tech to SEMICON SEA 2026

Chinese Top 3 Roll Laminator Manufacturer in 2026: Leading the Industry with Innovative Laminating Technology

Dr. Mohana Rao Patibandla Highlights 3 Advanced Pediatric Neurosurgery Techniques Following INDSPNCON 2026 Presentations

Troya Brings Delphine to Mill Valley, a new concept focused on Coastal Mediterranean cuisine